Financials in USD. Standardized financial statements.
A compact view of how Syndax Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $172.35M | $23.68M | $0 | $0 | $139.71M | $1.52M | $1.52M | $1.52M | $2.11M | $1.22M |
| Revenue Growth? | +627.8% | 0.0% | 0.0% | -100.0% | +9109.6% | 0.0% | 0.0% | -28.0% | +72.8% | 0.0% |
| Cost of Revenue? | $6.97M | $826,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $165.38M | $22.85M | $0 | $0 | $139.71M | $1.52M | $1.52M | $1.52M | $2.11M | $1.22M |
| Gross Margin? | +96.0% | +96.5% | 0.0% | 0.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $438.47M | $362.53M | $229.95M | $151.76M | $113.49M | $72.94M | $59.06M | $77.39M | $64.06M | $44.99M |
| Operating Income? | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M | -$71.42M | -$57.54M | -$75.88M | -$61.95M | -$43.77M |
| EBITDA? | -$251.63M | -$313.82M | -$209.14M | -$146.17M | $26.87M | -$70.29M | -$55.60M | -$73.88M | -$61.88M | -$43.68M |
| Income Before Tax | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M | -$73.16M | -$56.05M | -$73.96M | -$60.80M | -$44.47M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$76,000 | -$89,000 |
| Net Income? | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M | -$73.07M | -$55.95M | -$73.96M | -$60.80M | -$44.47M |
| EPS? | $-3.29 | $-3.73 | $-2.98 | $-2.46 | $0.48 | $-1.77 | $-1.84 | $-2.92 | $-2.90 | $-3.04 |
| Diluted EPS? | $-3.29 | $-3.73 | $-2.98 | $-2.46 | $0.48 | $-1.77 | $-1.84 | $-2.92 | $-2.90 | $-3.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality